Vbiosci's pipeline covers poultry, livestock and pets.
Vbiosci (Chinese: 鼎持生物), a leading innovative animal vaccine company, has completed hundreds of millions of CNY in Series B Round, which was jointly led by 3E Bioventures (Chinese: 本草资本) and China Reclamation Fund (Chinese: 中垦基金), followed by Longqing Capital (Chinese: 两山基金), Shenzhen Oriental Fortune Capital (Chinese: 东方富海), Hangzhou Zheke Investment Management (Chinese: 浙科投资), Suzhou Suxin Venture Capital (Chinese: 苏信创投) and Yijing Capital (Chinese: 沂景资本). WinX Capital (Chinese: 凯乘资本) served as the financial adviser.
This fund will be used for the R&D of the pipeline and industrial production of vaccines and biopharmaceuticals.
Vbiosci was established in 2016. The founding team is from well-known domestic and foreign pharmaceutical and animal health companies. The team has more than 20 years of experience in immunology and animal vaccine development. It has mastered all critical animal vaccine product development, application, and production technologies. The company benchmarks itself against international animal health enterprises, aims to master core technologies and become an independent research and development body.
The biopharmaceutical track is booming. Its competitors include Savbio ( Chinese: 北京华信农威生物科技有限公司), Ringpu (Chinese: 瑞普生物技术股份有限公司) and Hile-bio (Chinese: 上海海利生物技术股份有限公司).